Tag: rheumatoid arthritis (RA)

May 23, 2017 Off

Sanofi and Regeneron win FDA approval for its rheumatoid arthritis drug

By Dino Mustafić

The U.S. Food and Drug Administration (FDA) has approved Sanofi’s and Regeneron Pharmaceuticals’s Kevzara (sarilumab) for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX).

February 14, 2017 Off

European Commission approves Lilly’s and Incyte’s rheumatoid arthritis drug

By Dino Mustafić

Eli Lilly and Incyte Corporation have won European Commission’s marketing authorisation for Olumiant (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for the treatment of moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).